Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Review, H2 2016', provides in depth analysis on Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted pipeline therapeutics. The report provides comprehensive information on the Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - The report reviews Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics and enlists all their major and minor projects - The report assesses Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) Overview 7 Therapeutics Development 8 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Stage of Development 8 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Therapy Area 9 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Indication 10 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Pipeline Products Glance 11 Early Stage Products 11 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Companies 12 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Products under Development by Universities/Institutes 14 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 19 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Companies Involved in Therapeutics Development 21 Alchemia Limited 21 AstraZeneca Plc 22 Carmot Therapeutics Inc 23 Diabetica Limited 24 Eli Lilly and Company 25 Longevity Biotech, Inc 26 Sanofi 27 Zealand Pharma A/S 28 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Drug Profiles 29 AC-163794 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 DAJC-1 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 LBT-6030 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 SAR-438335 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Small Molecule to Agonize Gastric Inhibitory Polypeptide for Type 2 Diabetes - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Small Molecules to Agonize GLP-1 and GIP Receptors for Type 2 Diabetes and Obesity - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Synthetic Peptide 1 for Type 2 Diabetes and Obesity - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Synthetic Peptide 1 to Agonize GIPR for Alzheimer's Disease - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Synthetic Peptide to Agonize GIPR for Alzheimer's Disease - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Synthetic Peptide to Agonize GLP-1 Receptor and GIP Receptor for Diabetes - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Synthetic Peptides to Agonize GLP-1, GIP and Glucagon Receptors for Diabetes and Obesity - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 ZPDI-70 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 ZPI-98 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Dormant Projects 42 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Discontinued Products 43 Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) - Featured News & Press Releases 44 Sep 15, 2015: Zealand presents new preclinical data on its novel GIP peptide therapeutic, ZP-I-98, at the 51st EASD Annual Meeting 44 Jun 06, 2015: Presentations on ZP-DI-70, novel Zealand preclinical peptide therapeutics as a possible approach for the treatment of Type 2 diabetes and obesity at the American Diabetes Association's (ADA) 74th Scientific Sessions 44 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Assessment by Monotherapy/Combination Products, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 18 Number of Products by Stage and Molecule Type, H2 2016 20 Pipeline by Alchemia Limited, H2 2016 21 Pipeline by AstraZeneca Plc, H2 2016 22 Pipeline by Carmot Therapeutics Inc, H2 2016 23 Pipeline by Diabetica Limited, H2 2016 24 Pipeline by Eli Lilly and Company, H2 2016 25 Pipeline by Longevity Biotech, Inc, H2 2016 26 Pipeline by Sanofi, H2 2016 27 Pipeline by Zealand Pharma A/S, H2 2016 28 Dormant Projects, H2 2016 42 Discontinued Products, H2 2016 43
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
